NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.
NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.
NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.
NetScientific's mission is to build a transatlantic healthcare group focused on funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.
The Group is hosting its second annual Company’s Capital Markets Day in London on 14 June 2016 in London.
Francois Martelet, CEO, will host the session alongside other senior leaders from NetScientific and its portfolio companies to provide a comprehensive update on their shared strategic vision.
Speakers will include:
- Sir Richard Sykes, Chairman NetScientific
- Francois Martelet, CEO NetScientific
- Frank K Bedu-Addo, CEO PDS Biotechnology
- Gene Walther, CEO Vortex BioSciences
- David Ribeiro, CEO ProAxsis
- Larry Cohen, CEO Glycotest
- Steve Curd, CEO Wanda